Tse-Ling Fong, M.D.

Dr. Steven Q. Wang is a board-certified dermatologist and fellowship-trained Mohs micrographic surgeon focusing on the diagnosis, treatment and prevention of melanoma, squamous cell cancer, basal cell cancer and other skin cancers. Dr. Wang deploys technologies to detect melanoma and other skin cancers at early stages while avoiding unnecessary skin biopsies. He uses noninvasive treatment approaches and is capable of performing Mohs micrographic surgery and reconstruction to minimize scarring. Currently, Dr. Wang serves as the Medical Director of Dermatologic Oncology at Hoag Family Cancer Institute. His clinical practice is focused only on the prevention, diagnosis, and treatment of skin cancers. Dr. Wang understands the emotional and psychological stresses faced by patients and their family members. He strives to deliver compassionate and personalized care to every patient with a holistic approach while addressing their physical ailments and, more importantly, alleviating their emotional stress and psychological challenges associated with skin cancer. In addition to caring for patients, Dr. Wang is actively involved in clinical and basic research with a focus on melanoma detection, photoprotection and application of artificial intelligence in skin cancer detection. Dr. Wang has published more than 100 articles in peer-reviewed scientific journals and academic textbooks, written five books and has lectured throughout the world on the topics of skin cancer detection, treatment and prevention. Dr. Wang joined Hoag after spending 16 years at Memorial Sloan Kettering Cancer Center, where he served as the Head of Dermatology Section and Director of Dermatologic Surgery and Dermatology. He also served as associate professor at Weill Medical College of Cornell University in New York City during this period. Dr. Wang is the co-founder of the Nanodermatology Society and serves as the president of the Photodermatology Society and chair of the Photobiology Committee of the Skin Cancer Foundation. He has appeared on a number of television and radio programs and has been interviewed the Wall Street Journal, New York Times and Reuters.

Gary A. Ulaner, M.D., Ph.D., F.A.C.N.M., joins Hoag Family Cancer Institute as the Director of Molecular Imaging and Therapy.Dr. Ulaner was previously with Memorial Sloan Kettering Cancer Center, where he served as the PET/CT expert on the Breast Cancer Disease Management Team. Dual board-certified in radiology and nuclear medicine, Dr. Ulaner is a nationally recognized expert in the use of targeted imaging to help direct focused cancer therapies. He leads several National Institutes of Health (NIH) clinical trials in molecular imaging and therapeutics, including two active NIH R01 grants, and has received more than $8 million in extramural funding.Dr. Ulaner has received multiple honors throughout his career. He was elected Fellow of the American College of Nuclear Medicine, received an award for breast cancer research from the Susan Komen Foundation, and was the first Hal O'Brien Rising Star from the Society of Nuclear Medicine and Molecular Imaging (SNMMI), among other accolades.Dr. Ulaner has authored or co-authored more than 110 peer-reviewed manuscripts and has given more than 110 clinical presentations, both nationwide and internationally, in addition to writing the textbook Fundamentals of Oncologic PET/CT, published in both English and Spanish. He is also on the editorial boards of several leading clinical journals including: Radiology, Journal of Nuclear Medicine, European Journal of Nuclear Medicine and Molecular Imaging, and Clinical Nuclear Medicine.Dr. Ulaner completed his medical degree and a Ph.D. in Cancer Biology at Stanford University School of Medicine, an internship at Johns Hopkins Hospital, and his Radiology and Nuclear Medicine residencies at the University of Southern California.